New Combination Therapy Shows Promise for pMMR Advanced Endometrial Cancer in Phase Ib/II Trial geneonline.com
Relugolix, an oral GnRH receptor antagonist, is effective in treating uterine myomas and endometriosis. However, concerns persist regarding the venous thromboembolism (VTE) risk associated with its combination with oral estradiol …
Woman’s stage 4 endometrial cancer treated successfully with combination therapy MultiCare
Endometriosis is a chronic disorder characterized by abnormal endometrial tissue growth. This study evaluates a novel combination immunomodulatory treatment involving etanercept (ETN) and exosomes derived from human Wharton's jelly mesenchymal …
Background: Uterine fibroids (UFs) and endometriosis are gynecological conditions that significantly increase morbidity among women of reproductive age. Relugolix, a novel gonadotropin-releasing hormone receptor antagonist, is approved in combined therapy …
Exploring the Promise of E7386 and Lenvatinib Combination Therapy in Endometrial Carcinoma PharmExec
Impact of Combination Therapy: Evaluating the Influence of Lenvatinib and Pembrolizumab in Relapsed Endometrial Cancer OncLive
Endometriosis is a chronic estrogen-dependent inflammatory disease that significantly affects women's health. Polygala fallax Hemsl. (PFH), a traditional Zhuang medicine, has been frequently used for gynecological disorders. This study investigated …
Relugolix Combination Therapy Improves Pain, Functioning, and Quality of Life in Women with... Medical Dialogues
Relugolix Combination Therapy Improves Pain, Functioning, and Quality of Life in Women with Endometriosis: Study Medical Dialogues